BRCA2 and neoplasm: A common survival strategy in PARP inhibitor-resistant tumor cells is a restoration of BRCA1/2 function through secondary mutations or epigenetic de-repression of BRCA1 or BRCA2, thus restoring the high-fidelity repair of dsDNA breaks by HR DNA repair to escape the synthetic lethality caused by PARP inhibition [49,50].